on OXURION (EBR:OXUR)
Oxurion Secures Financing for Major Acquisition
On July 17, 2025, Oxurion NV, based in Leuven, announced securing financing for the acquisition of a 72% stake in Axiodis CRO. This move follows thorough due diligence and fulfills all necessary conditions. The financing was obtained from Atlas Special Opportunities, with the transaction set to close on August 1, 2025.
This strategic acquisition aligns with Oxurion's goal of developing an integrated platform focusing on clinical data. By incorporating Axiodis' expertise, Oxurion aims to become a strategic clinical research partner.
Further expansion plans include additional acquisitions in Europe, aiding in creating a leading hub dedicated to clinical data.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news